| Product No | EMEA/H/C/005436 |
|---|---|
| Brand Name | Minjuvi |
| Nonproprietary Name | tafasitamab |
| API | Tafasitamab |
| ATC Code | L01FX12 |
| Indications | Minjuvi is indicated in combination with lenalidomide followed by Minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT)., |
| Orphan Drug | yes |
| Generics | no |
| Marketing Authorization Holder | Incyte Biosciences Distribution B.V. |
| Status | Authorised(授权) |
| Authorization Date | 2021-08-26 |
| Version | 3 |
| Condition Approval | yes |
| Exceptions | no |
| Biosimilar | no |
| Details | 查看 (公众评估报告、授权细节、产品规格/剂型、标签、历史评估信息) |
Extended Information